Dividend Overview
Dividend Yield
—
Dividend / Share
—
Neurocrine Biosciences Inc
Biosciences, Inc. Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, endocrine, psychiatric and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders because you deserve brave science.
Earnings per share grew at a 50.0% CAGR.
Current Price
$131.78
+0.08%GoodMoat Value
$213.39
61.9% undervaluedDividend Yield
—
Dividend / Share
—
Market Cap
$13.14B
P/E Ratio
27.45
Forward P/E
—
EPS
$4.67
PEG Ratio
0.55
Book Value
$32.63
Dividend Yield
—
Profit Margin
16.73%
ROE
14.71%
Neurocrine Biosciences Inc (NBIX) dividend analysis including yield, payout history, and sustainability metrics.
P/E ratio: 27.45. Profit margin: 16.73%. Free cash flow: $748.70M. This page shows Neurocrine Biosciences Inc's dividend overview, key metrics, historical payout data, and dividend safety assessment to help income-focused investors evaluate the sustainability of dividend payments.
GoodMoat's dividend analyzer evaluates payout ratios, earnings coverage, and free cash flow coverage to determine how well supported Neurocrine Biosciences Inc's dividend payments are. Use this analysis alongside the company's financial statements and quality score to make informed income-investing decisions.